menu
    • menu
    [{"orgOrder":0,"company":"Trethera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Undisclosed"},{"orgOrder":0,"company":"Trethera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Undisclosed"},{"orgOrder":0,"company":"Trethera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Undisclosed"},{"orgOrder":0,"company":"Trethera","sponsor":"UCLA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ UCLA","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ UCLA"},{"orgOrder":0,"company":"Trethera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Undisclosed"},{"orgOrder":0,"company":"Trethera","sponsor":"Mabwell Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ Mabwell Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Mabwell Bioscience"},{"orgOrder":0,"company":"Trethera","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Cancer Institute"},{"orgOrder":0,"company":"Trethera","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Eye Institute","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Eye Institute"},{"orgOrder":0,"company":"Trethera","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Trethera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Undisclosed"},{"orgOrder":0,"company":"Trethera","sponsor":"UCLA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ UCLA","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ UCLA"},{"orgOrder":0,"company":"Trethera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Preclinical","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Trethera \/ Undisclosed"},{"orgOrder":0,"company":"Trethera","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Preclinical","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Trethera \/ National Institutes of Health"},{"orgOrder":0,"company":"Trethera","sponsor":"Small Business Innovation Research","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Preclinical","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ Small Business Innovation Research","highestDevelopmentStatusID":"4","companyTruncated":"Trethera \/ Small Business Innovation Research"},{"orgOrder":0,"company":"Trethera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Undisclosed"},{"orgOrder":0,"company":"UCLA","sponsor":"Trethera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"UCLA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"UCLA \/ Trethera","highestDevelopmentStatusID":"6","companyTruncated":"UCLA \/ Trethera"},{"orgOrder":0,"company":"Trethera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"IND Enabling","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trethera \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Trethera \/ Undisclosed"},{"orgOrder":0,"company":"Trethera","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Institutes of Health"},{"orgOrder":0,"company":"Trethera","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"IND Enabling","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Trethera \/ National Institutes of Health"},{"orgOrder":0,"company":"Trethera","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trethera \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Institutes of Health"}]

    Find Clinical Drug Pipeline Developments & Deals for TRE-515

    Menu

    TRE-515

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Trethera

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : National Institutes of Health

                            Deal Size : $1.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Trethera Gets $1.8M NIH Grant for TRE-515 in Crohn’s Disease

                            Details : The funding will support the development of TRE-515, a small molecule targeting dCK, for Crohn’s disease.

                            Product Name : TRE-515

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 23, 2025

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : National Institutes of Health

                            Deal Size : $1.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Trethera

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $2.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Trethera Awarded $2.3 Million NIH Grant to Study TRE-515 Combined with Radiation Therapy

                            Details : The funding will help the Trethera to advance it's TRE-515 with standard of care radiation therapy in mCRPC mouse models.

                            Product Name : TRE-515

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 26, 2025

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $2.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Trethera

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Trethera Awarded $3 Million NIH Grant to Advance TRE-515 for the Treatment of Lupus

                            Details : Trethera will leverage the funding to complete advanced studies of TRE-515, including toxicology, pharmacology, and efficacy testing, with the goal of initiating trials in lupus patients.

                            Product Name : TRE-515

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 19, 2025

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Trethera

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Fast Track to TRE-515 + Radiation for Metastatic Prostate Cancer Care

                            Details : TRE‑515 is a novel first in class oral therapy targeting cancer and autoimmune diseases via the nucleotide salvage pathway.

                            Product Name : TRE-515

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 09, 2025

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            UCLA

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            UCLA

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Trethera

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Trethera Secures New License, Strengthening TRE-515 Intellectual Property Portfolio

                            Details : Under the licensing agreement, Trethera will holds the exclusive rights for the clinical development of TRE-515, which is beingt evaluated for the treatment of neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 03, 2025

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Trethera

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Trethera

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : UCLA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trethera, UCLA Show TRE-515 Controls Immune Activation in Multiple Sclerosis

                            Details : TRE-515, targets the enzyme deoxycytidine kinase (dCK), currently being investigated for the treatment of multiple sclerosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 25, 2025

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : UCLA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Trethera

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Small Business Innovation Research

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Trethera Wins $2M NIH Grant for Pediatric Neurologic Disease Development

                            Details : The funding aims to support Trethera’s clinical stage and first-in-class drug, TRE-515 dCK inhibitor, which is being evaluated for the treatment of acute disseminated encephalomyelitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 16, 2024

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Small Business Innovation Research

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Trethera

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $0.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Trethera Receives NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated...

                            Details : The proceeds will be used for the preclinical development of Trethera’s first-in-class small molecule, TRE-515, an orally delivered, therapeutic engineered to inhibit dCK, for the treatment of acute disseminated encephalomyelitis, which holds the FDA O...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 14, 2023

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $0.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Trethera

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $0.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Trethera Receives Grant from National Institute of Allergy and Infectious Diseases for the Advancement of TRE-...

                            Details : The grant will fund Investigational New Drug (IND) enabling activities using TRE-515, a first-in-class deoxycytidine kinase (dCK) inhibitor, to treat systemic lupus erythematosus (SLE), a chronic autoimmune disease with significant morbidity and mortalit...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 27, 2023

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $0.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Trethera

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : National Cancer Institute

                            Deal Size : $2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Trethera Receives $2 Million National Cancer Institute Grant for Advancement of Clinically Relevant Biomarkers...

                            Details : The grant will fund additional patient dosing studies to identify predictive biomarkers of activity and target engagement of TRE-515, a first-in-class deoxycytidine kinase inhibitor, in solid tumors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 30, 2023

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : National Cancer Institute

                            Deal Size : $2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth